Acceleron Pharma Inc.
ALK7 binding proteins and uses thereof
Last updated:
Abstract:
This disclosure provides ALK7-binding proteins such as anti-ALK7 antibodies, and compositions and methods for making the ALK7-binding proteins. In certain embodiments the ALK7-binding proteins inhibit, or antagonize ALK7 activity. In addition, the disclosure provides compositions and methods for diagnosing and treating overweight, obesity, diabetes, overweight, obesity, type 2 diabetes, and their associated conditions; metabolic disorders, and other diseases or conditions that can be treated, prevented or ameliorated by targeting ALK7.
Status:
Grant
Type:
Utility
Filling date:
21 Apr 2017
Issue date:
10 Dec 2019